Who Will Pay? Building Market Need into the Biotech Value Journey

On 20 November 2026, SwedenBIO hosts a breakfast seminar at Bird & Bird in Stockholm on the biotech value journey. Early decisions about indication, cost and market need shape what a company is worth. The programme covers three steps: choosing an entry indication, establishing who will pay, and testing that case externally. Speakers include the CEOs of Medivir and Oncopeptides, who draw on their own company cases.

SwedenBIO’s Business Strategy group runs the session as part of the SwedenBIO Insights series. It suits founders, business developers and anyone shaping an early development or financing plan. Willingness to pay and market validation matter just as much in ATMP market access. The questions apply to advanced therapies too.

Registration details can be found on the event page.